Lack of Strategic Funding and Long-Term Job Security Threaten to Have Profound Effects on Cardiovascular Researcher Retention in Australia.


Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 06 04 2020
revised: 08 07 2020
accepted: 24 07 2020
pubmed: 26 8 2020
medline: 11 11 2020
entrez: 26 8 2020
Statut: ppublish

Résumé

Cardiovascular disease is the leading cause of death in Australia. Investment in research solutions has been demonstrated to yield health and a 9.8-fold return economic benefit. The sector, however, is severely challenged with success rates of traditional peer-reviewed funding in decline. Here, we aimed to understand the perceived challenges faced by the cardiovascular workforce in Australia prior to the COVID-19 pandemic. We used an online survey distributed across Australian cardiovascular societies/councils, universities and research institutes over a period of 6 months during 2019, with 548 completed responses. Inclusion criteria included being an Australian resident or an Australian citizen who lived overseas, and a current or past student or employee in the field of cardiovascular research. The mean age of respondents was 42±13 years, 47% were male, 85% had a full-time position, and 40% were a group leader or laboratory head. Twenty-three per cent (23%) had permanent employment, and 82% of full-time workers regularly worked >40 hours/week. Sixty-eight per cent (68%) said they had previously considered leaving the cardiovascular research sector. If their position could not be funded in the next few years, a staggering 91% of respondents would leave the sector. Compared to PhD- and age-matched men, women were less likely to be a laboratory head and to feel they had a long-term career path as a cardiovascular researcher, while more women were unsure about future employment and had considered leaving the sector (all p<0.05). Greater job security (76%) and government and philanthropic investment in cardiovascular research (72%) were highlighted by responders as the main changes to current practices that would encourage them to stay. Strategic solutions, such as diversification of career pathways and funding sources, and moving from a competitive to a collaborative culture, need to be a priority to decrease reliance on government funding and allow cardiovascular researchers to thrive.

Sections du résumé

BACKGROUND BACKGROUND
Cardiovascular disease is the leading cause of death in Australia. Investment in research solutions has been demonstrated to yield health and a 9.8-fold return economic benefit. The sector, however, is severely challenged with success rates of traditional peer-reviewed funding in decline. Here, we aimed to understand the perceived challenges faced by the cardiovascular workforce in Australia prior to the COVID-19 pandemic.
METHODS METHODS
We used an online survey distributed across Australian cardiovascular societies/councils, universities and research institutes over a period of 6 months during 2019, with 548 completed responses. Inclusion criteria included being an Australian resident or an Australian citizen who lived overseas, and a current or past student or employee in the field of cardiovascular research.
RESULTS RESULTS
The mean age of respondents was 42±13 years, 47% were male, 85% had a full-time position, and 40% were a group leader or laboratory head. Twenty-three per cent (23%) had permanent employment, and 82% of full-time workers regularly worked >40 hours/week. Sixty-eight per cent (68%) said they had previously considered leaving the cardiovascular research sector. If their position could not be funded in the next few years, a staggering 91% of respondents would leave the sector. Compared to PhD- and age-matched men, women were less likely to be a laboratory head and to feel they had a long-term career path as a cardiovascular researcher, while more women were unsure about future employment and had considered leaving the sector (all p<0.05). Greater job security (76%) and government and philanthropic investment in cardiovascular research (72%) were highlighted by responders as the main changes to current practices that would encourage them to stay.
CONCLUSION CONCLUSIONS
Strategic solutions, such as diversification of career pathways and funding sources, and moving from a competitive to a collaborative culture, need to be a priority to decrease reliance on government funding and allow cardiovascular researchers to thrive.

Identifiants

pubmed: 32839116
pii: S1443-9506(20)30396-6
doi: 10.1016/j.hlc.2020.07.010
pmc: PMC7442027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1588-1595

Informations de copyright

Copyright © 2020 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Heart Lung Circ. 2019 Feb;28(2):198-203
pubmed: 30654944
Eur J Prev Cardiol. 2017 Nov;24(17):1824-1830
pubmed: 28703626
J Am Coll Cardiol. 2018 Jul 24;72(4):419-429
pubmed: 30025578
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Heart Lung Circ. 2019 Aug;28(8):1144-1147
pubmed: 31230791
Eur Heart J. 2020 Jun 7;41(22):2092-2112
pubmed: 32511724
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Circulation. 2019 Feb 26;139(9):e44-e54
pubmed: 30674212
Lancet. 2019 Feb 9;393(10171):604-608
pubmed: 30739697
Lancet. 2019 Feb 9;393(10171):524-526
pubmed: 30739682
J Am Heart Assoc. 2019 Nov 5;8(21):e013296
pubmed: 31672080
Circulation. 2020 Jun 9;141(23):1838-1840
pubmed: 32286082

Auteurs

Rachel E Climie (RE)

Sports Cardiology and Diabetes and Population Health Laboratories, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia.

Jason H Y Wu (JHY)

The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.

Anna C Calkin (AC)

Central Clinical School, Monash University, Melbourne, Vic, Australia; Lipid Metabolism and Cardiometabolic Disease, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.

Niamh Chapman (N)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia.

Sally C Inglis (SC)

IMPACCT, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia.

Katrina M Mirabito Colafella (KM)

Department of Physiology and Biomedicine Discovery Institute, Monash University, Melbourne, Vic, Australia.

Dean S Picone (DS)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia.

Joanne T M Tan (JTM)

Vascular Research Centre, Lifelong Health Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.

Emma Thomas (E)

Centre for Online Health, Centre for Health Services Research, The University of Queensland, Brisbane, Qld, Australia.

Helena M Viola (HM)

School of Human Sciences, The University of Western Australia, Perth, WA, Australia.

Steven G Wise (SG)

School of Medical Sciences, Department of Physiology, University of Sydney, Sydney, NSW, Australia.

Andrew J Murphy (AJ)

Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.

Mark R Nelson (MR)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia.

Stephen J Nicholls (SJ)

Monash Cardiovascular Research Centre, Monash University, Melbourne, Vic, Australia.

Livia C Hool (LC)

School of Human Sciences, The University of Western Australia, Perth, WA, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.

Kerry Doyle (K)

Australian Cardiovascular Alliance, Sydney, NSW, Australia.

Gemma A Figtree (GA)

Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Francine Z Marques (FZ)

Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Vic, Australia; Baker Heart and Diabetes Institute, Melbourne, Vic, Australia. Electronic address: Francine.marques@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH